Abstract. The therapeutic options available for the treatment of advanced non-small cell lung cancer have increased over the past decade. Small molecule gene therapy has emerged as an effective therapy for the treatment of lung cancer in vitro and in vivo although it has not been tested in a clinical setting. In particular, therapies that target the negative feedback loop between p53 and murine double minute 2 (MDM2) provide a favorable outcome by maintaining activation of the tumor suppressor gene p53. The present study used transfection to simultaneously knockdown MDM2 expression using small interfering (si)RNA, and overexpress wild-type p53 in H1299 cells. The effects of transfection on cell proliferation and cell cycle progression were determined using an MTT assay and flow cytometry, and the effects on mRNA and protein expression were determined by western blotting and reverse transcription polymerase chain reaction. The results indicated that simultaneously knocking down MDM2 and overexpressing p53 was able to inhibit proliferation and induce G 1 cell cycle arrest in H1299 cells, compared with either alone. These findings indicated that the si-MDM2-p53 co-expression plasmid may induce cell cycle arrest, and may be considered a novel therapeutic option for the treatment of lung cancer.
Introduction
Lung cancer continues to be the leading cause of cancer-associated mortality in men and women worldwide (1) . The average survival rate for a patient diagnosed with lung cancer is <5 years. Among the lung cancer subtypes, non-small cell lung cancer is the most common (2, 3) . In an attempt to overcome this problem, a growing number of therapeutic interventions have been developed to target lung cancer, including targeted thermal ablation, radiation therapy and biological therapy. In addition, small molecule gene therapy is considered an effective therapy for the treatment of lung cancer. In particular, using a combined-gene therapeutic approach has been reported to increase curative effects, and is often more effective than single gene therapy alone (4, 5) .
p53 is a well-known tumor suppressor gene that can activate genes responsible for regulating cell proliferation, apoptosis, cell cycle control, senescence, transcriptional regulation and DNA repair (6) . In addition, p53 is able to regulate the tumor microenvironment by inhibiting the development of tumor vasculature. Approximately half of all human tumors contain a mutation in p53, which is associated with poor patient prognosis. Murine double minute 2 (MDM2) is an E3 ubiquitin ligase that can induce p53 inactivation by directly binding to it and promoting its ubiquitination (7) . Ultimately, MDM2-mediated ubiquitination of p53 leads to its degradation by the 26S proteasome. Consequently, increased expression levels of MDM2 can inhibit p53 activity, thereby preventing its tumor suppressor function. Therefore, the present study knocked down MDM2 expression using small interfering (si)RNA to promote p53 transcriptional activity, and determined its effects on a lung cancer model (5, 8) .
One important characteristic of tumors is uncontrolled cell growth. Under normal conditions, cell proliferation is tightly regulated by the cell cycle. The eukaryotic cell cycle is regulated by the cyclin-dependent kinase (CDK) family (9) , which contains protein kinases that comprise catalytic (CDK) and regulatory subunits (cyclin). Cyclin D-CDK4/6 and cyclin E-CDK2 are two types of G 1 cyclin-CDK complexes that are required for entry into S phase of the cell cycle. Notably, increasing p53 levels have been reported to result in an upregulation in the protein expression levels of p21, which is an inhibitor of CDKs that can prevent the development of G 1 CDK-cyclin complexes (10) . In addition, p21 can prevent DNA synthesis and inhibit proliferating cell nuclear antigen; therefore, by increasing p53 levels, it is possible to induce p21 to cause G 1 phase cell cycle arrest. Small molecule gene therapy has received increasing amounts of attention; however, due to the complexity of tumors, a single gene therapy strategy is unlikely to be successful (11) . Conversely, a combined-gene therapeutic approach has been reported to be more effective (4, 7) . Therefore, the present study induced co-expression of MDM2-specific siRNA and wild-type p53 (si-MDM2-p53) in H1299 lung cancer cells, and determined its effects on cell cycle progression and cancer cell viability.
Materials and methods
Cell culture and transfection. H1299 lung cancer cells (Sangon Biotech Co., Ltd., Shanghai, China) were cultured in RPMI-1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (Hyclone; GE Healthcare Life Sciences) and penicillin-streptomycin (1,000 µg/ml) at 37˚C and in 5% CO 2 . When cells reached 70-90% confluence, they were transfected with scrambled siRNA [5'-GAT CCG TAT AAG TCA ACT GTT GACttcaagagaGTC AAC AGT TGA CTT ATA CTT TTT TGG AAA-3' (sense strand) and 5'-AGC TTT TCC AAA AAA GTA TAA GTC AAC TGT TGA CtctcttgaaGTC AAC AGT TGA CTT ATA CG-3' (antisense strand)] The lower case letters indicate non-homologus sequences. The plasmid of si-MDM2, the plasmid of p53 and the plasmid of si-MDM2-p53 (Jilin University, Jilin, China) were prepared as previously described (4, 5) . The plasmid si-MDM2 sequence: forward, 5'-CGT CGC GAG GGC TAT GA A CTA ATG ACCC-3' and reverse, 5'-GCA GAT CTT GCT TCG CGA TGT ACG GGC C-3'. The plamid p53 sequence: forward, 5'-CCA TCT ACA AGC AGT CAC AG-3' and reverse, 5'-CAA ATC TAC AAG CAG TCA CAG-3'. PGCsiRNA-MDM2 (si-MDM2), pcDNA3.1-p53 (p53), pcDNA3.1-p53/U6 siRNA-MDM2 and p53 (si-MDM2-p53) (Jilin University, Jilin, China), these eukaryotic expression vectors were used to transfect the plasmids into cells using a transfection reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA). When the cell density reached to 85-90%, 6 µg of every plasmid was used to transfect into cells at 37˚C. Following 48 h transfection, cells were then collected to analyze cell activity, protein and gene expression, and cell cycle progression.
MTT assay. A total of ~4.5x10 3 cells/well were incubated in a 96-well plate, and were cultured under normal growth conditions prior to transfection with si-MDM2, p53 or si-MDM2-p53 plasmids (Jilin University). Cell viability was measured by adding 20 µl MTT (Sangon Biotech Co., Ltd.) to each well 24, 48 and 72 h post-transfection. Following 4 h, 150 µl dimethyl sulfoxide (Sangon Biotech Co., Ltd.) was used to dissolve the crystals at room temperature, and the absorbance was measured at 490 nm using a microplate reader.
Flow cytometric analysis (FCM) to determine cell cycle progression.
Cells were collected for FCM by washing twice with cold PBS (centrifuged at 1,000 x g for 5 min/wash, 4˚C) and were digested with 0.25% EDTA-free trypsin. Following two further washes, 75% ethanol was added to the cells, and the cells were cultured at 4˚C overnight. Subsequently, the cells were centrifuged at 4°C, 1,000 x g for 5 min, and the ethanol was discarded before washing the cells two more times. Finally, ~8x10 4 cells were resuspended in 200-500 µl PBS, stained with propidium iodide (100 µg/ml), and maintained in the dark for 30 min at room temperature. Cell cycle progression was analyzed using the Epics-XL-MCL flow cytometer (Beckman Coulter, Inc., Brea, CA, USA).
Western blot analysis. Cells were lysed with 100-150 µl radioimmunoprecipitation assay buffer supplemented with phenylmethylsulfonyl fluoride (Roche Diagnostics, Basel, Switzerland), and were sonicated 3-5 times (0˚C, 5 sec every time) using ultrasound pyrolysis apparatus (Tomy Seiko Co., Ltd., Tokyo, Japan) to shear the cells. Subsequently, the cells were centrifuged for 20 min at 4˚C, 12,000 x g, and the protein content in the supernatant was measured using Bradford reagent (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The lysates (20 µg protein) were separated by 12% SDS-PAGE and were transferred onto polyvinylidene fluoride membranes at 0˚C for 50 min, then blocking with 5 % nonfat milk at room temperature for 1 h (EMD Millipore, Bedford, MA, USA). The protein expression levels of p53, p21, cyclin D1 and MDM2 were detected by western blot analysis. Rabbit polyclonal anti-p21 (1:2,000; cat. no. 10355-1-AP) and rabbit polyclonal anti-p53 (1:1,000; cat. no. 10442-1-AP), were purchased from ProteinTech Group, Inc. (Chicago, IL, USA). Mouse polyclonal anti-cyclin D1 (1:200; cat. no. sc-450) and MDM2 (1:200; cat. no. sc-81218), were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA); and rabbit polyclonal anti-pan-actin (1:1,000; cat. no. 8456) was purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). All the primary antibodies were incubated at room temperature for 4 h. Anti-rabbit (1:1,000; cat. no. SA00001-2) and anti-mouse (1:1,000; cat. no. SA00001-1) were purchased from ProteinTech Group, Inc. (Chicago, IL, USA), they were incubated at room temperature for 1 h. Proteins were detected using an enhanced chemiluminescence kit (cat. no. 120702-74; Advansta, Inc., Menio Park, CA, USA). The images were captured using a Syngene Bio Imaging System (Synoptics, Cambridge, UK).
Reverse transcription semi-quantitative polymerase chain reaction [RT-(sq)PCR]
. H1299 cells were harvested from a 6-well plate. The cells were washed twice, following this 500 µl TRIzol ® (Invitrogen; Thermo Fisher Scientific, Inc.) was added to each well and incubated at room temperature for 5 min. Subsequently, trichloromethane was added, and following centrifugation at 4˚C, 2,000 x g for 5 min, minisopropanol was added to the aqueous phase. Finally, 75% ethanol was used to wash RNA prior to resuspending it in RNase-free water. Subsequently, 5 µg total RNA (purified following DNase I treatment) from each sample was converted to cDNA using an RT kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA), which was performed according to the manufacturer's protocol. The primer sequences and reaction conditions are presented in Tables I and II . The PCR products were separated on a 2% agarose gel, and visualized by ethidium bromide staining then images were captured using the image processing system (Tanon, 1600R; Tanon Science and Technology Co., Ltd., Shanghai, China). Statistical analysis was then carried out.
Statistical analysis. Data are presented as the mean ± standard deviation. SPSS 19.0 (IBM Corp., Armonk, NY, USA) was used to statistically analyze the data using single factor analysis of variance and least significant difference to test the multiple comparisons. P<0.05 was considered to indicate a statistically significant difference.
Results

Effects of si-MDM2, p53 or si-MDM2-p53 plasmids on the proliferation of H1299 cells.
To determine whether simultaneously inhibiting MDM2 and overexpressing wild-type p53 was able to inhibit the proliferation of lung cancer cells, H1299 cells were transfected with si-MDM2, p53 or si-MDM2-p53 plasmids and cell proliferation was analyzed at 24, 48 and 72 h using an MTT assay. The results indicated that si-MDM2, p53 and si-MDM2-p53 plasmids inhibited cell proliferation (Fig. 1) . Notably, after 48 h the si-MDM2-p53 plasmid was able to inhibit cell proliferation by ~50%, which was more than p53 or si-MDM2 alone (P<0.05). Taken together, these results indicated that the si-MDM2-p53 plasmid may significantly inhibit the proliferation of H1299 cells. 
Phase -------------------------------------------------------------------------------
CDK4, cyclin-dependent kinase 4; MDM2, murine double minute 2. Figure 1 . Effects of si-MDM2, p53 and si-MDM2-53 plasmids on cell viability. H1299 cells were transfected with si-MDM2, p53 or si-MDM2-53 plasmids and cell viability was measured using an MTT assay. Effects of si-MDM2, p53 or si-MDM2-53 plasmids on cell cycle arrest. In order to determine whether manipulating the Figure 2 . Effects of p53 and MDM2 knockdown on the cell cycle progression of H1299 cells. Cells were transfected with si-MDM2, p53 or si-MDM2-p53 plasmids for 48 h and propidium iodide was then used to analyze cell cycle progression using the Epics-XL-MCL flow cytometer. si-MDM2, small interfering RNA-murine double minute 2. The relevant data is exhibited in Table III as the mean ± the standard deviation of the mean of triplicate experiments. (Fig. 2) . Furthermore, FCM indicated that co-expression of si-MDM2 and the p53 overexpression plasmid resulted in a significant increase in the number of cells in G 1 phase cell cycle arrest, compared with the cell transfected with si-MDM2 or p53 plasmids alone (P<0.05). The percentages of cells in G 1 phase from each group are presented in Table III .
Effects of si-MDM2, p53 or si-MDM2-53 plasmids on the expression of cell cycle-associated genes and proteins in H1299 cells. To investigate the mechanism underlying the effects of the si-MDM2, p53 and si-MDM2-53 plasmids on G 1 phase cell cycle arrest and cell proliferation, the mRNA expression levels of p21, cyclin D1, CDK4 and MDM2 were determined by RT-(sq)PCR, and the protein expression levels of p53, p21, cyclin D1 and MDM2 were determined by western blot analysis, respectively (Figs. 3 and 4) . The results indicated that the protein and mRNA expression levels of p53 and p21 were significantly increased when the H1299 cells were transfected with si-MDM2, p53 or si-MDM2-53 plasmids, compared with the control or scramble groups (P<0.05). In addition, there was a significant decrease in the protein and mRNA expression levels of cyclin D1 and MDM2, and a significant decrease in the mRNA expression levels of cyclin D1, MDM2 and CDK4 (P<0.05).
Discussion
Effective therapeutic strategies for the treatment of lung cancer remain a major obstacle, particularly because patients often present at terminal stages. Furthermore, the low diagnostic accuracy of clinical staging delays the optimum time for effective treatment (12, 13) . Small molecule gene therapies for lung cancer are considered a potentially effective therapeutic approach; however, care must be taken to identify the appropriate combination of gene therapies for the effective treatment of lung cancer.
The results of the present study demonstrated that p53 serves an important role in regulating the oncogenic behavior of H1299 cells. Under normal conditions, p53 is suppressed by MDM2, which results in the maintenance of low p53 nuclear levels (6, (14) (15) (16) . Notably, MDM2 inhibits p53-mediated apoptosis, DNA repair and cell cycle arrest; however, in response to stress, including oxidative or DNA replication stress, hypoxia or oncogenic activation, the negative loop between p53 and MDM2 is broken, and p53 expression is stabilized by post-translational modifications (17, 18) . Specifically, MDM2 releases p53, thereby allowing p53 to translocate to the nucleus, bind its target genes and activate downstream genes that combat the source of stress. In the present study, it was indicated that si-MDM2-p53 was able to significantly inhibit the proliferation of H1299 cells, and that si-MDM2 and p53 co-expression could increase the expression of p53 (19, 20) .
Regulation of the cell cycle is a complex procedure that is regulated by complex mechanisms, and is controlled by critical regulatory genes, including CDKs and their regulatory inhibitors (21, 22) . It has previously been reported that p21 is associated with cell cycle regulation. For example, p21 is an inhibitor of CDKs that inhibits the expression of G 1 CDK-cyclin complexes. Notably, p21 is a downstream target gene of p53 (23) . Upon being subjected to stress, p53 protein levels are increased, which results in a corresponding increase in p21 protein levels. In addition, CDK2, CDK4 and CDK6 are downregulated by p21 (24, 25) . In the present study, FCM was used to detect alterations in the cell cycle progression of H1299 cells in response to si-MDMD2, p53 overexpression or both. A significant increase in G 1 phase cell cycle arrest was detected following transfection with the si-MDM2-53 plasmid, compared with si-MDM2 or p53 alone.
In conclusion, the present study used a si-MDM2 and p53 co-expression plasmid to disrupt the negative feedback loop between MDM2 and p53, and to increase the expression levels of p53 (26, 27) . The results indicated that in H1299 lung cancer cells transfected with the si-MDM2-53 plasmid, p53 and p21 expression levels were increased, whereas CDK4 and cyclin D1 were downregulated, at the protein and mRNA levels. These results suggested that downregulation of MDM2 and upregulation of p53 may induce inhibition of H1299 cell proliferation and cell cycle arrest. Taken together, the use of a si-MDM2-p53 co-expression plasmid may offer a novel gene therapy that targets lung cancer.
